#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

ProfileTweet
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Welcome to tonight #LCSM chat @lcsmchat where we will cover topics from #WCLC21 and #ESMO21
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Welcome to tonight #LCSM chat @lcsmchat where we will cover topics from #WCLC21 and #ESMO21
Charu Aggarwal, MD, MPH @CharuAggarwalMD
I am your moderator for tonight. I am a thoracic medical oncologist at @PennCancer @PennMedicine, focusing on improving lives of patients with #LungCancer #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: I am your moderator for tonight. I am a thoracic medical oncologist at @PennCancer @PennMedicine, focusing on improving lives of patients with #LungCancer #LCSM @lcsmchat
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Its great to see many of you here, we will get started in about 5 minutes. Remember to include #LCSM in ALL your tweets so the other chat participants can see them @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Its great to see many of you here, we will get started in about 5 minutes. Remember to include #LCSM in ALL your tweets so the other chat participants can see them @lcsmchat
Janet Freeman-Daily @JFreemanDaily
Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21.
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21.
kristen kimball @KimballKristen
RT @JFreemanDaily: Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21.
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21.
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: I am your moderator for tonight. I am a thoracic medical oncologist at @PennCancer @PennMedicine, focusing on improving lives of patients with #LungCancer #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Its great to see many of you here, we will get started in about 5 minutes. Remember to include #LCSM in ALL your tweets so the other chat participants can see them @lcsmchat
Deb Smith 🌻 @debsmithbeach
Deb here from lovely NH, glad to have this info. #LCSM https://t.co/aG7zJOx22l
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @JFreemanDaily: Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21.
#LCSM Chat @lcsmchat
I already see some of you out there. Please introduce yourselves #LCSM
#LCSM Chat @lcsmchat
RT @debsmithbeach: Deb here from lovely NH, glad to have this info. #LCSM https://t.co/aG7zJOx22l
Janet Freeman-Daily @JFreemanDaily
RT @debsmithbeach: Deb here from lovely NH, glad to have this info. #LCSM https://t.co/aG7zJOx22l
Sanjay Mukhopadhyay @smlungpathguy
@CharuAggarwalMD @lcsmchat #LCSM basement dwelling slide reader here 🙏🏾
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Tim here. #lcsm
#LCSM Chat @lcsmchat
@debsmithbeach Hi Deb! We sure miss out on this beauty in SoCal. #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Our discussion for tonight will be based on 5 topics labeled T1...T5, and we encourage you to chime in using A1...A5, and don't forget the #LCSM hashtag! @lcsmchat
Janet Freeman-Daily @JFreemanDaily
@debsmithbeach Good to see you Deb! #LCSM
#LCSM Chat @lcsmchat
RT @smlungpathguy: @CharuAggarwalMD @lcsmchat #LCSM basement dwelling slide reader here 🙏🏾
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Our discussion for tonight will be based on 5 topics labeled T1...T5, and we encourage you to chime in using A1...A5, and don't forget the #LCSM hashtag! @lcsmchat
kristen kimball @KimballKristen
Hi everyone, it's Kris (Kimball) from Boston, former caregiver, staying in touch. #LCSM
#LCSM Chat @lcsmchat
@smlungpathguy @CharuAggarwalMD What would we do without our pathologists? Right, @TimAllenMDJD? #lcsm
Janet Freeman-Daily @JFreemanDaily
@smlungpathguy @CharuAggarwalMD @lcsmchat Hi Sanjay and Tim! #LCSM
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Tim here. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Howdy, @smlungpathguy! #lcsm
Cindy Barthi @cindyb1333
RT @CharuAggarwalMD: I am your moderator for tonight. I am a thoracic medical oncologist at @PennCancer @PennMedicine, focusing on improving lives of patients with #LungCancer #LCSM @lcsmchat
Lung Cancer Sux @LungCancerSux
Hi @CharuAggarwalMD @BrendonStilesMD ! Looking forward to an informative evening! #LCSM
#LCSM Chat @lcsmchat
@TimAllenMDJD Hey, Tim! Hope things are improving where you are. #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Our discussion for tonight will be based on 5 topics labeled T1...T5, and we encourage you to chime in using A1...A5, and don't forget the #LCSM hashtag! @lcsmchat
#LCSM Chat @lcsmchat
RT @KimballKristen: Hi everyone, it's Kris (Kimball) from Boston, former caregiver, staying in touch. #LCSM
#LCSM Chat @lcsmchat
@KimballKristen Hey Kris! #lcsm
Janet Freeman-Daily @JFreemanDaily
@LungCancerFaces @lcsmchat And welcome as always to my #LCSM sidekick @LungCancerFaces who's operating the @LCSMChat account tonight.
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Can't argue with @lcsmchat! #lcsm
#LCSM Chat @lcsmchat
RT @LungCancerSux: Hi @CharuAggarwalMD @BrendonStilesMD ! Looking forward to an informative evening! #LCSM
Sanjay Mukhopadhyay @smlungpathguy
@JFreemanDaily @CharuAggarwalMD @lcsmchat Hi Janet! Just remember: whatever goes wrong, it’s always the pathologist’s fault! #LCSM 😜
#LCSM Chat @lcsmchat
@LungCancerSux @CharuAggarwalMD @BrendonStilesMD Hey you! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @LungCancerFaces @lcsmchat And welcome as always to my #LCSM sidekick @LungCancerFaces who's operating the @LCSMChat account tonight.
Janet Freeman-Daily @JFreemanDaily
@KimballKristen Welcome Kristen! #LCSM
#LCSM Chat @lcsmchat
RT @smlungpathguy: @JFreemanDaily @CharuAggarwalMD @lcsmchat Hi Janet! Just remember: @JFreemanDaily @CharuAggarwalMD @lcsmchat Hi Janet! Just remember: whatever goes wrong, it’s always the pathologist’s fault! #LCSM 😜
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Howdy @JFreemanDaily! #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM
#LCSM Chat @lcsmchat
@smlungpathguy @JFreemanDaily @CharuAggarwalMD No, it’s always the mother’s fault. Ask any therapist. #lcsm
kristen kimball @KimballKristen
@JFreemanDaily Hi Janet :) #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM
Christina Lizaso @btrfly12
RT @lcsmchat: TODAY! #LCSM Chat 10/7 5pm PT, 8pm ET: TODAY! #LCSM Chat 10/7 5pm PT, 8pm ET: “Best in Show - #LungCancer highlights from #WCLC21 & #ESMO2021 moderated by @CharuAggarwalMD. IMPORTANT: READ MORE HERE PRIOR TO CHAT: https://t.co/vxtSQNKFfz… Please RT to spread the word! New to chats? Read this https://t.co/CPRCw8YoQ3
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Thank you! Getting some better but more to do. #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN
NCI Cancer Stats @NCICancerStats
Did you know there are two main types of #LungCancer: small cell and non-small cell? Watch our “Did you know?” video on lung cancer to learn more. https://t.co/gZjTuen3jL #LCSM
Sanjay Mukhopadhyay @smlungpathguy
RT @CharuAggarwalMD: Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#DynamicDuo #lcsm
Joseph Steward @jsteward2930
RT @NCICancerStats: Did you know there are two main types of #LungCancer: Did you know there are two main types of #LungCancer: small cell and non-small cell? Watch our “Did you know?” video on lung cancer to learn more. https://t.co/gZjTuen3jL #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO
#LCSM Chat @lcsmchat
@TommaHargraves Hey Tomma! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO
conciergedoc @DrFerdowsi
RT @CharuAggarwalMD: A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN
conciergedoc @DrFerdowsi
RT @CharuAggarwalMD: A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN
Pembrolizumab 💜🤍💚 @LauCuapa
RT @AndreaAnampaG: Latin American patients are more likely to have lung cancer with EGFR mutations (Peru 🇵🇪 had 51.1%) It is important to do genotyping as they may benefit from EGFR inhibitors @Meyersonlab of @DanaFarber #Disparities #AACRdisp21 #SurvOnc #HOFellows #lcsm https://t.co/cfXl0WtOZD
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Glad to have this option available, through @FDAOncology's #AcceleratedApproval for our patients, as yet another targeted therapy for #NSCLC @kRasKickers @lcsmchat #LCSM https://t.co/ZtiIPvmNN6
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO
Kaushal Parikh @kaushalpar
A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @kaushalpar: A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
It’s Rami Manochakian. Oncologist @MayoCancerCare Joining the wonderful #LCSM chat @lcsmchat for important discussion on #LUNGCANCER updates from #WCLC21 & #ESMO21 . Session moderated by Outstanding colleague & expert @CharuAggarwalMD #CancerEducation
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Glad to have this option available, through @FDAOncology's #AcceleratedApproval for our patients, as yet another targeted therapy for #NSCLC @kRasKickers @lcsmchat #LCSM https://t.co/ZtiIPvmNN6
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: Glad to have this option available, through @FDAOncology's #AcceleratedApproval for our patients, as yet another targeted therapy for #NSCLC @kRasKickers @lcsmchat #LCSM https://t.co/ZtiIPvmNN6
Rosemary Conway @SLPChitChat
RT @lcsmchat: It’s time for another #LCSM Chat! @CharuAggarwalMD will break down the most promising & important Lung Cancer research from 2 major conferences: #WCLC21 & #ESMO21. Join us this Thurs 10/7 5pm PT, 8pm ET to stay up-to-date on the “Best in Show.” Please RT to spread the word! https://t.co/XNYYcunjGu
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN
Janet Freeman-Daily @JFreemanDaily
RT @kaushalpar: A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @kaushalpar: A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM
Peggy Dennis @peggyddennis
@lcsmchat Peggy here from Denver #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Glad to have this option available, through @FDAOncology's #AcceleratedApproval for our patients, as yet another targeted therapy for #NSCLC @kRasKickers @lcsmchat #LCSM https://t.co/ZtiIPvmNN6
Kaushal Parikh @kaushalpar
RT @CharuAggarwalMD: Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @kaushalpar: A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM
Eric K. Singhi, MD @esinghimd
@lcsmchat Eric here 👋🏽 Oncology fellow with an interest in thoracic oncology in Houston, TX. First time joining the chat! Excited to be here #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat
erikbelleville @BellevilleErik
RT @StephenVLiu: Why not block out your calendar now for the big lung cancer meetings for 2022? Even if going virtually! Sometimes it's nice to look ahead #LCSM AACR: April 8-13 (New Orleans) ASCO: June 3-7 (Chicago) ELCC: March 30-April 2 (Prague) WCLC: Aug 6-9 (Vienna) ESMO: Sept 9-13 (Paris) https://t.co/llEfNNJ31k
Charu Aggarwal, MD, MPH @CharuAggarwalMD
We also saw data from clincal trial of T-DxD (trastuzumab deruxtecan) in patients with #Her2 Mutant NSCLC, making this subset extremely actionable. Presented by Dr. Li, and published in @NEJM #LCSM @lcsmchat #ESMO21 https://t.co/yHgNCXPeqz
Lung Cancer Sux @LungCancerSux
@CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat Please cover data, if any, for NSCLC without actionable targets #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@esinghimd @lcsmchat Welcome Eric! #LCSM
#LCSM Chat @lcsmchat
RT @RManochakian: It’s Rami Manochakian. Oncologist @MayoCancerCare Joining the wonderful #LCSM chat @lcsmchat for important discussion on #LUNGCANCER updates from #WCLC21 & #ESMO21 . Session moderated by Outstanding colleague & expert @CharuAggarwalMD #CancerEducation
#LCSM Chat @lcsmchat
RT @peggyddennis: @lcsmchat Peggy here from Denver #LCSM
Janet Freeman-Daily @JFreemanDaily
@peggyddennis @lcsmchat Welcome Peggy! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @esinghimd: @lcsmchat Eric here 👋🏽 Oncology fellow with an interest in thoracic oncology in Houston, TX. First time joining the chat! Excited to be here #lcsm
Kaushal Parikh @kaushalpar
A1. Also notable mention for mobo for accelerated approval last month for same indication #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@LungCancerSux @FDAOncology @kRasKickers @lcsmchat Yes, we will- coming up shortly! #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: We also saw data from clincal trial of T-DxD (trastuzumab deruxtecan) in patients with #Her2 Mutant NSCLC, making this subset extremely actionable. Presented by Dr. Li, and published in @NEJM #LCSM @lcsmchat #ESMO21 https://t.co/yHgNCXPeqz
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Welcome to #lcsm @esinghimd
Janet Freeman-Daily @JFreemanDaily
@esinghimd @lcsmchat Glad to have you with us, Eric. #LCSM
#LCSM Chat @lcsmchat
RT @LungCancerSux: @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat Please cover data, if any, for NSCLC without actionable targets #LCSM
Joseph Steward @jsteward2930
RT @CharuAggarwalMD: We also saw data from clincal trial of T-DxD (trastuzumab deruxtecan) in patients with #Her2 Mutant NSCLC, making this subset extremely actionable. Presented by Dr. Li, and published in @NEJM #LCSM @lcsmchat #ESMO21 https://t.co/yHgNCXPeqz
#LCSM Chat @lcsmchat
RT @kaushalpar: A1. Also notable mention for mobo for accelerated approval last month for same indication #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: We also saw data from clincal trial of T-DxD (trastuzumab deruxtecan) in patients with #Her2 Mutant NSCLC, making this subset extremely actionable. Presented by Dr. Li, and published in @NEJM #LCSM @lcsmchat #ESMO21 https://t.co/yHgNCXPeqz
Kaushal Parikh @kaushalpar
RT @CharuAggarwalMD: Welcome to tonight #LCSM chat @lcsmchat where we will cover topics from #WCLC21 and #ESMO21
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters
Sanjay Mukhopadhyay @smlungpathguy
RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @RManochakian: A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters
Rosemary Conway @SLPChitChat
#LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @RManochakian: A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM
#LCSM Chat @lcsmchat
RT @RManochakian: A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters
Kaushal Parikh @kaushalpar
RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
Worth noting that #Mobocertinib is an oral drug while #amivantamab-vmjw is IV. Also, they have different toxicity profiles. #LCSM
Janet Freeman-Daily @JFreemanDaily
@LungCancerSux @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat You can read what the topics will be in the @lcsmchat blog at https://t.co/92JI6dxOOI #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Howdy @CharuAggarwalMD! #lcsm
Sanjay Mukhopadhyay @smlungpathguy
Mobocertinib! @CharuAggarwalMD and #LCSM bringing info from the latest oncology conferences to the folks on Twitter! So much changes so fast in lung cancer.
#LCSM Chat @lcsmchat
@SLPChitChat Welcome, Rosemary! If anyone else is out there watching, please send us a blank tweet with #lcsm in it.
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM
#LCSM Chat @lcsmchat
RT @RManochakian: Worth noting that #Mobocertinib is an oral drug while #amivantamab-vmjw is IV. Also, they have different toxicity profiles. #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @LungCancerSux @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat You can read what the topics will be in the @lcsmchat blog at https://t.co/92JI6dxOOI #LCSM
#LCSM Chat @lcsmchat
RT @smlungpathguy: Mobocertinib! @CharuAggarwalMD and #LCSM bringing info from the latest oncology conferences to the folks on Twitter! So much changes so fast in lung cancer.
kristen kimball @KimballKristen
@SLPChitChat Hi Rosemary! #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @smlungpathguy: Mobocertinib! @CharuAggarwalMD and #LCSM bringing info from the latest oncology conferences to the folks on Twitter! So much changes so fast in lung cancer.
Janet Freeman-Daily @JFreemanDaily
RT @kaushalpar: A1. Also notable mention for mobo for accelerated approval last month for same indication #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @JFreemanDaily: @LungCancerSux @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat You can read what the topics will be in the @lcsmchat blog at https://t.co/92JI6dxOOI #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters
Dave Bjork @bjork5
Hi friends, sorry I’m late. #lcsm
Lindsay McGrath @LindsayMcGrat12
#LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
Bottom Line- most patients benefit. It is important to test! Couldn’t have said it better @CharuAggarwalMD #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: Worth noting that #Mobocertinib is an oral drug while #amivantamab-vmjw is IV. Also, they have different toxicity profiles. #LCSM
Eric K. Singhi, MD @esinghimd
@RManochakian A1. Strong point! Infusion-related reactions especially with the initial dose of amivantamab seem common #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @smlungpathguy: Mobocertinib! @CharuAggarwalMD and #LCSM bringing info from the latest oncology conferences to the folks on Twitter! So much changes so fast in lung cancer.
Janet Freeman-Daily @JFreemanDaily
RT @lcsmchat: @SLPChitChat Welcome, Rosemary! If anyone else is out there watching, please send us a blank tweet with #lcsm in it.
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @RManochakian: Bottom Line- most patients benefit. It is important to test! Couldn’t have said it better @CharuAggarwalMD #LCSM
#LCSM Chat @lcsmchat
As always, we are retweeting as we go from this account, so you can look back on anything that you’ve missed. We post a transcript, too. #LCSM
Janet Freeman-Daily @JFreemanDaily
@bjork5 Welcome Dave! #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Other drugs have been studied in this setting before (Her2 Mutant #NSCLC) - T-DxD seems to provide an advantage over others (remember no direct comparison) > Afatinib > Neratinib > Dacomitinib > Neratinib > Pyrotinib > Poziotinib #LCSM @lcsmchat
#LCSM Chat @lcsmchat
@LindsayMcGrat12 Hi Lindsay! Thanks for joining us. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @esinghimd: @RManochakian A1. Strong point! Infusion-related reactions especially with the initial dose of amivantamab seem common #lcsm
#LCSM Chat @lcsmchat
RT @RManochakian: Bottom Line- most patients benefit. It is important to test! Couldn’t have said it better @CharuAggarwalMD #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: Other drugs have been studied in this setting before (Her2 Mutant #NSCLC) - T-DxD seems to provide an advantage over others (remember no direct comparison) > Afatinib > Neratinib > Dacomitinib > Neratinib > Pyrotinib > Poziotinib #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Other drugs have been studied in this setting before (Her2 Mutant #NSCLC) - T-DxD seems to provide an advantage over others (remember no direct comparison) > Afatinib > Neratinib > Dacomitinib > Neratinib > Pyrotinib > Poziotinib #LCSM @lcsmchat
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Destiny LUNG-02 represents a new standard of care for patients with #Her2Mutant #NSCLC #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @esinghimd: @RManochakian A1. Strong point! Infusion-related reactions especially with the initial dose of amivantamab seem common #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Other drugs have been studied in this setting before (Her2 Mutant #NSCLC) - T-DxD seems to provide an advantage over others (remember no direct comparison) > Afatinib > Neratinib > Dacomitinib > Neratinib > Pyrotinib > Poziotinib #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Destiny LUNG-02 represents a new standard of care for patients with #Her2Mutant #NSCLC #LCSM @lcsmchat
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: Destiny LUNG-02 represents a new standard of care for patients with #Her2Mutant #NSCLC #LCSM @lcsmchat
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
A1: Presented at #ESMO21 @myESMO results of #CHRYSALIS-2 trial: #Amivantamab + #Lazertinib in #EGFR mutant #NSCLC post Osimertinib & post chemo. RR 21%, CBR 51%, mTTR 1.5m #LCSM @lcsmchat
Charu Aggarwal, MD, MPH @CharuAggarwalMD
It's time to move on! T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? @lcsmchat #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @RManochakian: A1: Presented at #ESMO21 @myESMO results of #CHRYSALIS-2 trial: #Amivantamab + #Lazertinib in #EGFR mutant #NSCLC post Osimertinib & post chemo. RR 21%, CBR 51%, mTTR 1.5m #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Destiny LUNG-02 represents a new standard of care for patients with #Her2Mutant #NSCLC #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @RManochakian: A1: Presented at #ESMO21 @myESMO results of #CHRYSALIS-2 trial: #Amivantamab + #Lazertinib in #EGFR mutant #NSCLC post Osimertinib & post chemo. RR 21%, CBR 51%, mTTR 1.5m #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: It's time to move on! T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? @lcsmchat #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: A1: Presented at #ESMO21 @myESMO results of #CHRYSALIS-2 trial: #Amivantamab + #Lazertinib in #EGFR mutant #NSCLC post Osimertinib & post chemo. RR 21%, CBR 51%, mTTR 1.5m #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: It's time to move on! T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? @lcsmchat #LCSM
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
@esinghimd Indeed reaction common and strong #LCSM
#LCSM Chat @lcsmchat
#lcsm A question from a patient
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@peggyddennis @NEJM @lcsmchat Amazing! Thank you for paving the way! #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A2: A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ
Dave Bjork @bjork5
@RManochakian @CharuAggarwalMD Yes 💯 to Biomarker testing! #lcsm every patient deserves access. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: A2: A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
Indeed new standard of care. #Her2 must add/tested for among important list of other actionable mutations in #NSCLC #lcsm @lcsmchat
#LCSM Chat @lcsmchat
RT @bjork5: @RManochakian @CharuAggarwalMD Yes 💯 to Biomarker testing! #lcsm every patient deserves access. #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#TheFutureIsBright #lcsm
kristen kimball @KimballKristen
RT @CharuAggarwalMD: A2: A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Absolutely #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @RManochakian: Indeed new standard of care. #Her2 must add/tested for among important list of other actionable mutations in #NSCLC #lcsm @lcsmchat
Dave Bjork @bjork5
@JFreemanDaily Hey Janet! #lcsm 😊
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc
#LCSM Chat @lcsmchat
RT @RManochakian: Indeed new standard of care. #Her2 must add/tested for among important list of other actionable mutations in #NSCLC #lcsm @lcsmchat
kristen kimball @KimballKristen
RT @bjork5: @RManochakian @CharuAggarwalMD Yes 💯 to Biomarker testing! #lcsm every patient deserves access. #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Great @CharuAggarwalMD! #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ
Lucia Viola MD @LuciaViola9
RT @IASLC: Surgical resection remains the gold standard for patients diagnosed w/early-stage #lungcancer; Since the early 1990s, VATS lobectomy has been acknowledged as an effective (and preferred) minimally invasive approach for lung cancer surgery. Read More: https://t.co/6wIlEKIspM #LCSM
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
@bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @RManochakian: @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM
kristen kimball @KimballKristen
RT @CharuAggarwalMD: One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc
Dave Bjork @bjork5
RT @CharuAggarwalMD: A2: A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Word #lcsm
#LCSM Chat @lcsmchat
RT @RManochakian: @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM
Eric K. Singhi, MD @esinghimd
@RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm
Sanjay Mukhopadhyay @smlungpathguy
RT @CharuAggarwalMD: One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @esinghimd: @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm
Dave Bjork @bjork5
RT @RManochakian: @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
#LiquidBiopsy is a must for every patient with advanced #NSCLC. It gives us results sooner and it’s a simple blood test. #lcsm @lcsmchat
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Another important paper looked at perceptions of biomarker testing across US oncology physicians @LUNGevity > There is a need for patient education > Guidelines + Best Practices to guide implementation of molecular testing #LCSM @lcsmchat https://t.co/rI1Vo0wMPT
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @esinghimd: @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm
#LCSM Chat @lcsmchat
RT @esinghimd: @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm
#LCSM Chat @lcsmchat
RT @RManochakian: #LiquidBiopsy is a must for every patient with advanced #NSCLC. It gives us results sooner and it’s a simple blood test. #lcsm @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Another important paper looked at perceptions of biomarker testing across US oncology physicians @LUNGevity > There is a need for patient education > Guidelines + Best Practices to guide implementation of molecular testing #LCSM @lcsmchat https://t.co/rI1Vo0wMPT
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T3: What new ideas did #WCLC21 and #ESMO21 offer regarding adjuvant immunotherapy? #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: #LiquidBiopsy is a must for every patient with advanced #NSCLC. It gives us results sooner and it’s a simple blood test. #lcsm @lcsmchat
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @esinghimd: @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm
#LCSM Chat @lcsmchat
I see you @CroixDenise! Thanks for joining us. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @RManochakian: #LiquidBiopsy is a must for every patient with advanced #NSCLC. It gives us results sooner and it’s a simple blood test. #lcsm @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Another important paper looked at perceptions of biomarker testing across US oncology physicians @LUNGevity > There is a need for patient education > Guidelines + Best Practices to guide implementation of molecular testing #LCSM @lcsmchat https://t.co/rI1Vo0wMPT
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: Another important paper looked at perceptions of biomarker testing across US oncology physicians @LUNGevity > There is a need for patient education > Guidelines + Best Practices to guide implementation of molecular testing #LCSM @lcsmchat https://t.co/rI1Vo0wMPT
Sanjay Mukhopadhyay @smlungpathguy
I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T3: T3: What new ideas did #WCLC21 and #ESMO21 offer regarding adjuvant immunotherapy? #LCSM @lcsmchat
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: T3: T3: What new ideas did #WCLC21 and #ESMO21 offer regarding adjuvant immunotherapy? #LCSM @lcsmchat
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A3. Adjuvant Therapy is simply systemic therapy administered after surgery in an attempt to reduce risk of recurrence #LCSM @lcsmchat https://t.co/LHCPDJc17h
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @smlungpathguy: I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@smlungpathguy We will always need our pathology friends! #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: A3. Adjuvant Therapy is simply systemic therapy administered after surgery in an attempt to reduce risk of recurrence #LCSM @lcsmchat https://t.co/LHCPDJc17h
Janet Freeman-Daily @JFreemanDaily
RT @smlungpathguy: I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: A3. Adjuvant Therapy is simply systemic therapy administered after surgery in an attempt to reduce risk of recurrence #LCSM @lcsmchat https://t.co/LHCPDJc17h
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @smlungpathguy We will always need our pathology friends! #LCSM
Kaushal Parikh @kaushalpar
A3. Impower150 paves way for atezo adj after chemo. Ques is, what pdl1 cutoff are we comfortabld with? 1% vs 50%? And is DFS enough for changing practice? #lcsm
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
#LCSM @lcsmchat T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? A2: One common message from all presentations: #BiomarkersTesting/#NgsTesting is A MUST from #LiquidBiopsy & #Tissue
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T3: T3: What new ideas did #WCLC21 and #ESMO21 offer regarding adjuvant immunotherapy? #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @smlungpathguy: I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A3. Adjuvant Therapy is simply systemic therapy administered after surgery in an attempt to reduce risk of recurrence #LCSM @lcsmchat https://t.co/LHCPDJc17h
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Privileged to be here to help our patients, @CharuAggarwalMD #lcsm
#LCSM Chat @lcsmchat
RT @kaushalpar: A3. Impower150 paves way for atezo adj after chemo. Ques is, what pdl1 cutoff are we comfortabld with? 1% vs 50%? And is DFS enough for changing practice? #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @kaushalpar: A3. Impower150 paves way for atezo adj after chemo. Ques is, what pdl1 cutoff are we comfortabld with? 1% vs 50%? And is DFS enough for changing practice? #lcsm
#LCSM Chat @lcsmchat
RT @RManochakian: #LCSM @lcsmchat T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? A2: One common message from all presentations: #BiomarkersTesting/#NgsTesting is A MUST from #LiquidBiopsy & #Tissue
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Privileged to be here to help our patients, @CharuAggarwalMD #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
#IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: #LCSM @lcsmchat T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? A2: One common message from all presentations: #BiomarkersTesting/#NgsTesting is A MUST from #LiquidBiopsy & #Tissue
Dave Bjork @bjork5
@esinghimd @RManochakian @CharuAggarwalMD 💯💯💯 #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @kaushalpar: A3. Impower150 paves way for atezo adj after chemo. Ques is, what pdl1 cutoff are we comfortabld with? 1% vs 50%? And is DFS enough for changing practice? #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0
#LCSM Chat @lcsmchat
Thank you for joining us tonight @DrBonillaOnc @BrainTumorDoc #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Dr. @HwakeleeMD presented this data at #ASCO21 and updated by @EnriquetaFelip @ESMO21 #LCSM @lcsmchat https://t.co/BG3A2juWh0
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Dr. @HwakeleeMD presented this data at #ASCO21 and updated by @EnriquetaFelip @ESMO21 #LCSM @lcsmchat https://t.co/BG3A2juWh0
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: Dr. @HwakeleeMD presented this data at #ASCO21 and updated by @EnriquetaFelip @ESMO21 #LCSM @lcsmchat https://t.co/BG3A2juWh0
Eric K. Singhi, MD @esinghimd
@CharuAggarwalMD @lcsmchat A3. We had an update on IMPower010 at WCLC21. Adjuvant atezo improved DFS in resected stage 2-3A NSCLC. Will DFS ➡️ OS? Which subgroup of pts, based on PD-L1 %, should receive? #lcsm
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
A3: Probable new standard of care. especially for high #PDL1. Adjuvant #Atezolizumab after adjuvant chemo for resected early stage #NSCLC #LCSM
Preventive Medicine Bot @PreventiveBot
RT @NCICancerStats: Did you know there are two main types of #LungCancer: Did you know there are two main types of #LungCancer: small cell and non-small cell? Watch our “Did you know?” video on lung cancer to learn more. https://t.co/gZjTuen3jL #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @esinghimd: @CharuAggarwalMD @lcsmchat A3. We had an update on IMPower010 at WCLC21. Adjuvant atezo improved DFS in resected stage 2-3A NSCLC. Will DFS ➡️ OS? Which subgroup of pts, based on PD-L1 %, should receive? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Dr. @HwakeleeMD presented this data at #ASCO21 and updated by @EnriquetaFelip @ESMO21 #LCSM @lcsmchat https://t.co/BG3A2juWh0
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @RManochakian: A3: A3: Probable new standard of care. especially for high #PDL1. Adjuvant #Atezolizumab after adjuvant chemo for resected early stage #NSCLC #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @esinghimd: @CharuAggarwalMD @lcsmchat A3. We had an update on IMPower010 at WCLC21. Adjuvant atezo improved DFS in resected stage 2-3A NSCLC. Will DFS ➡️ OS? Which subgroup of pts, based on PD-L1 %, should receive? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: A3: A3: Probable new standard of care. especially for high #PDL1. Adjuvant #Atezolizumab after adjuvant chemo for resected early stage #NSCLC #LCSM
#LCSM Chat @lcsmchat
Thank you for joining us @FmprZahra @jakelee0711 #lcsm
fabiotavora @fabiotavora
@smlungpathguy Fabio here, #pulmonarypathologist from Brazil. I still think we can do so much and go so much deeper in tissue than #liquidbiopsy, but am hopeful the latter will be a breakthrough in screening and early detection #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Recently published in @lancet, we did see benefit in patients with PDL1 >50%. If one year of adjuvant atezolizumab will benefit all patients post resection, and chemotherapy, remains to be seen. It is also important to remember to perform NGS #LCSM @lcsmchat
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: Recently published in @lancet, we did see benefit in patients with PDL1 >50%. If one year of adjuvant atezolizumab will benefit all patients post resection, and chemotherapy, remains to be seen. It is also important to remember to perform NGS #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @esinghimd: @CharuAggarwalMD @lcsmchat A3. We had an update on IMPower010 at WCLC21. Adjuvant atezo improved DFS in resected stage 2-3A NSCLC. Will DFS ➡️ OS? Which subgroup of pts, based on PD-L1 %, should receive? #lcsm
#LCSM Chat @lcsmchat
RT @RManochakian: A3: A3: Probable new standard of care. especially for high #PDL1. Adjuvant #Atezolizumab after adjuvant chemo for resected early stage #NSCLC #LCSM
#LCSM Chat @lcsmchat
RT @fabiotavora: @smlungpathguy Fabio here, #pulmonarypathologist from Brazil. I still think we can do so much and go so much deeper in tissue than #liquidbiopsy, but am hopeful the latter will be a breakthrough in screening and early detection #LCSM
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
A3: One of The future questions: #Adjuvant immunotherapy vs #neoadjuvant immunotherapy or chemo + immuno. . #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Recently published in @lancet, we did see benefit in patients with PDL1 >50%. If one year of adjuvant atezolizumab will benefit all patients post resection, and chemotherapy, remains to be seen. It is also important to remember to perform NGS #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @RManochakian: A3: One of The future questions: A3: One of The future questions: #Adjuvant immunotherapy vs #neoadjuvant immunotherapy or chemo + immuno. . #LCSM @lcsmchat
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @RManochakian: A3: One of The future questions: A3: One of The future questions: #Adjuvant immunotherapy vs #neoadjuvant immunotherapy or chemo + immuno. . #LCSM @lcsmchat
Andres F. Cardona @AndresFCardonaZ
RT @CharuAggarwalMD: #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T4: What did #WCLC21 and #ESMO21 presentations suggest about using immunotherapy when brain metastases are present? #LCSM @lcsmchat
Geoff Oxnard, MD @geoff_oxnard
RT @CharuAggarwalMD: Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: T4: T4: What did #WCLC21 and #ESMO21 presentations suggest about using immunotherapy when brain metastases are present? #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Recently published in @lancet, we did see benefit in patients with PDL1 >50%. If one year of adjuvant atezolizumab will benefit all patients post resection, and chemotherapy, remains to be seen. It is also important to remember to perform NGS #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: A3: One of The future questions: A3: One of The future questions: #Adjuvant immunotherapy vs #neoadjuvant immunotherapy or chemo + immuno. . #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T4: T4: What did #WCLC21 and #ESMO21 presentations suggest about using immunotherapy when brain metastases are present? #LCSM @lcsmchat
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A4. We have already seen results from CM-9LA and at #WCLC21, we saw subset analyses of patients with treated brain mets (Dr. Carbone) #LCSM @lcsmchat https://t.co/nqS9cUcSJe
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: A4. We have already seen results from CM-9LA and at #WCLC21, we saw subset analyses of patients with treated brain mets (Dr. Carbone) #LCSM @lcsmchat https://t.co/nqS9cUcSJe
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: A4. We have already seen results from CM-9LA and at #WCLC21, we saw subset analyses of patients with treated brain mets (Dr. Carbone) #LCSM @lcsmchat https://t.co/nqS9cUcSJe
#LCSM Chat @lcsmchat
Thank you for joining us @AngelaAchurie @bradylabupenn @SamahAlRehaily #lcsm
#LCSM Chat @lcsmchat
Thank you for joining us @AndresFCardonaZ @geoff_oxnard #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T4: T4: What did #WCLC21 and #ESMO21 presentations suggest about using immunotherapy when brain metastases are present? #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A4. We have already seen results from CM-9LA and at #WCLC21, we saw subset analyses of patients with treated brain mets (Dr. Carbone) #LCSM @lcsmchat https://t.co/nqS9cUcSJe
Angela Churie Kallhauge @AngelaAchurie
@lcsmchat @bradylabupenn @SamahAlRehaily Thank you. Very inspiring chat. Gives so much hope knowing that finally more is happening for us #lcsm
#LCSM Chat @lcsmchat
RT @AngelaAchurie: @lcsmchat @bradylabupenn @SamahAlRehaily Thank you. Very inspiring chat. Gives so much hope knowing that finally more is happening for us #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @AngelaAchurie: @lcsmchat @bradylabupenn @SamahAlRehaily Thank you. Very inspiring chat. Gives so much hope knowing that finally more is happening for us #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A4. Patients that have treated brain mets benefit from IO, as well as those without BM #WCLC21 @lcsmchat #lcsm https://t.co/jIMIvQhVHE
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: A4. Patients that have treated brain mets benefit from IO, as well as those without BM #WCLC21 @lcsmchat #lcsm https://t.co/jIMIvQhVHE
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A4. Patients that have treated brain mets benefit from IO, as well as those without BM #WCLC21 @lcsmchat #lcsm https://t.co/jIMIvQhVHE
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A4. Immunotherapy is safe and effective in patients with treated brain mets, as seen across many other clinical trials. HR represents a reduction in risk of death #Immunotherapy #WCLC21 #LCSM @lcsmchat https://t.co/0atHTftCkr
Janet Freeman-Daily @JFreemanDaily
There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: A4. Immunotherapy is safe and effective in patients with treated brain mets, as seen across many other clinical trials. HR represents a reduction in risk of death #Immunotherapy #WCLC21 #LCSM @lcsmchat https://t.co/0atHTftCkr
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: A4. Patients that have treated brain mets benefit from IO, as well as those without BM #WCLC21 @lcsmchat #lcsm https://t.co/jIMIvQhVHE
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A4. What about untreated brain metastases? ATEZO-Brain was a clinical trial presented at #WCLC21 with promising early results #lcsm @lcsmchat https://t.co/dSjecZa1U3
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: A4. What about untreated brain metastases? ATEZO-Brain was a clinical trial presented at #WCLC21 with promising early results #lcsm @lcsmchat https://t.co/dSjecZa1U3
Janet Freeman-Daily @JFreemanDaily
This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM
Sanjay Mukhopadhyay @smlungpathguy
RT @fabiotavora: @smlungpathguy Fabio here, #pulmonarypathologist from Brazil. I still think we can do so much and go so much deeper in tissue than #liquidbiopsy, but am hopeful the latter will be a breakthrough in screening and early detection #LCSM
#LCSM Chat @lcsmchat
Thank you for joining us @DrFerdowsi @CanaryLauren #lcsm
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
#LCSM @lcsmchat #Immunotherapy can help with brain mets in #NSCLC. Not as good or as often as #TargetedTherapies though. Need More studies/more trials/more biomarkers.
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @JFreemanDaily: This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @RManochakian: #LCSM @lcsmchat #Immunotherapy can help with brain mets in #NSCLC. Not as good or as often as #TargetedTherapies though. Need More studies/more trials/more biomarkers.
gilberto lopes @GlopesMd
RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM
Santhosh Ambika @RenoHemonc
RT @CharuAggarwalMD: Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: #LCSM @lcsmchat #Immunotherapy can help with brain mets in #NSCLC. Not as good or as often as #TargetedTherapies though. Need More studies/more trials/more biomarkers.
Angela Churie Kallhauge @AngelaAchurie
RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
A4. These results are encouraging, some additional questions remain, that we look forward to being answered in the future #LCSM @lcsmchat https://t.co/YJgmxDFtqS
#LCSM Chat @lcsmchat
Thank you for joining us @PatelOncology @RenoHemonc #lcsm
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
It’s an era of hope for #NSCLC patients. So much happening indeed. #LCSM @lcsmchat @JFreemanDaily
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T5: What other #WCLC21 and #ESMO21 presentations or ideas captured you interest? #LCSM @lcsmchat
#LCSM Chat @lcsmchat
Thank you for joining us @GlopesMd @nuria_dios #lcsm
Denise Cutlip @dennycee
Checking in late. Grateful you archive these. #lcsm
Janet Freeman-Daily @JFreemanDaily
@RManochakian @lcsmchat Immune checkpoint inhibitor (#ICI) drugs may not be as effective treating the brain as #targetedtherapy, but since the two types of drug usually treat different patient populations, it's still a win. #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @CharuAggarwalMD: A4. These results are encouraging, some additional questions remain, that we look forward to being answered in the future #LCSM @lcsmchat https://t.co/YJgmxDFtqS
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A4. Immunotherapy is safe and effective in patients with treated brain mets, as seen across many other clinical trials. HR represents a reduction in risk of death #Immunotherapy #WCLC21 #LCSM @lcsmchat https://t.co/0atHTftCkr
#LCSM Chat @lcsmchat
RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A4. What about untreated brain metastases? ATEZO-Brain was a clinical trial presented at #WCLC21 with promising early results #lcsm @lcsmchat https://t.co/dSjecZa1U3
#LCSM Chat @lcsmchat
RT @JFreemanDaily: This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM
#LCSM Chat @lcsmchat
RT @RManochakian: #LCSM @lcsmchat #Immunotherapy can help with brain mets in #NSCLC. Not as good or as often as #TargetedTherapies though. Need More studies/more trials/more biomarkers.
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @JFreemanDaily: @RManochakian @lcsmchat Immune checkpoint inhibitor (#ICI) drugs may not be as effective treating the brain as #targetedtherapy, but since the two types of drug usually treat different patient populations, it's still a win. #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: @RManochakian @lcsmchat Immune checkpoint inhibitor (#ICI) drugs may not be as effective treating the brain as #targetedtherapy, but since the two types of drug usually treat different patient populations, it's still a win. #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: A4. These results are encouraging, some additional questions remain, that we look forward to being answered in the future #LCSM @lcsmchat https://t.co/YJgmxDFtqS
#LCSM Chat @lcsmchat
RT @RManochakian: It’s an era of hope for #NSCLC patients. So much happening indeed. #LCSM @lcsmchat @JFreemanDaily
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T5: T5: What other #WCLC21 and #ESMO21 presentations or ideas captured you interest? #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: A4. These results are encouraging, some additional questions remain, that we look forward to being answered in the future #LCSM @lcsmchat https://t.co/YJgmxDFtqS
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @RManochakian @lcsmchat Immune checkpoint inhibitor (#ICI) drugs may not be as effective treating the brain as #targetedtherapy, but since the two types of drug usually treat different patient populations, it's still a win. #LCSM
Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey
RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Thank you to everyone for joining us tonight at #LCSM @lcsmchat!
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
@JFreemanDaily @lcsmchat Definitely @JFreemanDaily I tell my patients with #NSCLC on the first visit the same thing. If we find a mutation, will have a good #TargetedTherapy and if we don’t, will have #ImmunoTherapy. Hope and goal of research though to keep finding more #Biomarkers. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @RManochakian: @JFreemanDaily @lcsmchat Definitely @JFreemanDaily I tell my patients with #NSCLC on the first visit the same thing. If we find a mutation, will have a good #TargetedTherapy and if we don’t, will have #ImmunoTherapy. Hope and goal of research though to keep finding more #Biomarkers. #LCSM
Tomma Hargraves @TommaHargraves
@CharuAggarwalMD @lcsmchat My first #lcsm@lcsmchat… lots of good info! Thanks
Lung Cancer Sux @LungCancerSux
RT @RManochakian: @JFreemanDaily @lcsmchat Definitely @JFreemanDaily I tell my patients with #NSCLC on the first visit the same thing. If we find a mutation, will have a good #TargetedTherapy and if we don’t, will have #ImmunoTherapy. Hope and goal of research though to keep finding more #Biomarkers. #LCSM
Janet Freeman-Daily @JFreemanDaily
We have a few minutes left in #LCSM Chat--any closing thoughts? Any guesses on what's next in research?
Janet Freeman-Daily @JFreemanDaily
I'm seeing more studies for antibody drug conjugates (ADCs)--the antibody targets cancer cells, and then delivers a chemotherapy directly to the cells. #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm
#LCSM Chat @lcsmchat
#lcsm
#LCSM Chat @lcsmchat
RT @TommaHargraves: @CharuAggarwalMD @lcsmchat My first #lcsm@lcsmchat… lots of good info! Thanks
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @TimAllenMDJD: I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Thank you to everyone for joining us tonight at #LCSM @lcsmchat!
Janet Freeman-Daily @JFreemanDaily
@TommaHargraves @CharuAggarwalMD @lcsmchat Glad you were able to join us, Tomma! Most #LCSM chats are more conversational, but tonight we're up against MLB playoffs and football ...
Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation @RManochakian
Great #LCSM chat with great colleagues, patients, caregivers & advocates. Thank U all! #TogetherAgainstLungCancer It’s en era of hope for #NSCLC patients. Always remember: #KnowledgeConquersCancer @lcsmchat @JFreemanDaily @CharuAggarwalMD @TimAllenMDJD
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @TommaHargraves @CharuAggarwalMD @lcsmchat Glad you were able to join us, Tomma! Most #LCSM chats are more conversational, but tonight we're up against MLB playoffs and football ...
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: I'm seeing more studies for antibody drug conjugates (ADCs)--the antibody targets cancer cells, and then delivers a chemotherapy directly to the cells. #LCSM
#LCSM Chat @lcsmchat
RT @RManochakian: @JFreemanDaily @lcsmchat Definitely @JFreemanDaily I tell my patients with #NSCLC on the first visit the same thing. If we find a mutation, will have a good #TargetedTherapy and if we don’t, will have #ImmunoTherapy. Hope and goal of research though to keep finding more #Biomarkers. #LCSM
#LCSM Chat @lcsmchat
RT @RManochakian: Great #LCSM chat with great colleagues, patients, caregivers & advocates. Thank U all! #TogetherAgainstLungCancer It’s en era of hope for #NSCLC patients. Always remember: #KnowledgeConquersCancer @lcsmchat @JFreemanDaily @CharuAggarwalMD @TimAllenMDJD
#LCSM Chat @lcsmchat
RT @JFreemanDaily: We have a few minutes left in #LCSM Chat--any closing thoughts? Any guesses on what's next in research?
kristen kimball @KimballKristen
So much happening! Thank you for this topic tonight. #LCSM
Carol Rizkalla @Carol2Path
RT @smlungpathguy: I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM
Lung Cancer Sux @LungCancerSux
Many new faces! Thanks to all! #LCSM
Denise Cutlip @dennycee
Thank you #LCSM
Janet Freeman-Daily @JFreemanDaily
Thank you @CharuAggarwalMD for moderating tonight's #LCSM Chat and compiling a great set of tweets about #WCLC21 and #ESMO21 presentations! You had a great first outing as a moderator.
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @JFreemanDaily: Thank you @CharuAggarwalMD for moderating tonight's #LCSM Chat and compiling a great set of tweets about #WCLC21 and #ESMO21 presentations! You had a great first outing as a moderator.
#LCSM Chat @lcsmchat
So many have been watching and liking tweets. I know we haven’t been able to recognize all of you. Very sorry for that. Thank you for joining! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Thank you @CharuAggarwalMD for moderating tonight's #LCSM Chat and compiling a great set of tweets about #WCLC21 and #ESMO21 presentations! You had a great first outing as a moderator.
Allison Rosen M.S. @ARosen380
CALLING ALL AYA’s do you want to help improve reproductive health after cancer? Please take the time to fill this out and please share it to anyone you know! #cancer #ayacsm #crcsm #lcsm #bcsm @AdvocateCollab @EK_Drake @ogcancerpatient
Preventive Medicine Bot @PreventiveBot
RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM
Preventive Medicine Bot @PreventiveBot
RT @JFreemanDaily: This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM
Preventive Medicine Bot @PreventiveBot
RT @TimAllenMDJD: I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm
Arturo Loaiza-Bonilla, MD MSEd @DrBonillaOnc
RT @lcsmchat: Thank you for joining us tonight @DrBonillaOnc @BrainTumorDoc #lcsm
Arturo Loaiza-Bonilla, MD MSEd @DrBonillaOnc
RT @CharuAggarwalMD: T5: T5: What other #WCLC21 and #ESMO21 presentations or ideas captured you interest? #LCSM @lcsmchat
Drew Moghanaki @DrewMoghanaki
Starting in 15 minutes if you're curious what these people have to say. #lcsm
#LCSM content from Twitter.